Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
News|Slideshows|July 18, 2019
Treatment Intensification in Type 2 Diabetes: 3 Cases
Author(s)Sudipa Sarkar, MD
When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?
Advertisement
Choice of antihyperglycemic agent after metformin can now be selected to also address comorbidites often seen in T2DM patients. Each of the 3 patients in this short case quiz presents a challenge as well as an opportonity to optimize diabetes care. Â
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
5